Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DXd + Pyrotinib in 1L HER2+ Metastatic Breast Cancer
NCT06245824Phase 4Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2024
- Primary completion
- Mar 2026
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trastuzumab deruxtecan and pyrotinib in breast cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Recommended dose of pyrotinib combined with T-DXd and Progression Free Survival at 49 months. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
trastuzumab deruxtecanpyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06245824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06245824.